2.78 CME

Clinical Approach to Recurrent Implantation Failure

Speaker: Dr. Aseemita Debata

Senior Consultant Obstetrician & Gynecologist, Founder, Tatvam Health Cloudnine | Motherhood | CK Birla | Max Hospitals, Gurgaon

Summary

Recurrent Implantation Failure (RIF) is a challenging yet common entity in IVF, defined by varying criteria historically. The latest SRE 2023 definition individualizes RIF, considering a patient's cumulative predicted implantation chance, typically exceeding a 60% threshold without resulting in pregnancy, to trigger further investigation. True RIF affects less than 5% of IVF couples, carrying a significant psychological burden.
Implantation itself is a three-step synchronized dialogue between a competent embryo and a receptive endometrium: apposition (loose contact on D6-D7), adhesion (firm attachment on D7-D8), and invasion (embedding into the decidua on D8-D11). Any disruption in this cascade can lead to failure.
Causes of RIF are categorized into embryonic, endometrial, systemic, and iatrogenic/lifestyle factors. Embryonic factors, contributing 40-60% of RIF, include genetically abnormal or suboptimal embryos, high sperm DNA fragmentation, parental balanced translocations, and suboptimal lab conditions. Endometrial factors (25-35%) encompass anatomical issues (fibroids, polyps, adhesions, septum, adenomyosis, hydrosalpinx), chronic endometritis, very thin endometrium, and a displaced window of implantation.
Systemic factors such as thyroid dysfunction, uncontrolled diabetes, hyperprolactinemia, and severe vitamin D3 deficiency can also impair implantation. While inherited thrombophilias and immunological factors (e.g., peripheral NK cells, cytokine ratios) are sometimes discussed, they are not routinely recommended for investigation unless specific clinical or familial history suggests their involvement. Endometrial microbiome, dominated by lactobacillus for a healthy environment, is an emerging area of research.
Investigation of RIF follows a tiered approach: first, confirming it's a true RIF based on the 60% cumulative threshold; second, optimizing basics like lifestyle, endocrine function, and re-evaluating stimulation protocols and lab quality; third, assessing uterine anatomy (3D ultrasound, hysteroscopy) and endometrial receptivity (e.g., chronic endometritis screening); fourth, focusing on embryo quality (day 5 blastocyst transfer, PGTA for selected cases). Further, more complex testing is reserved for specific historical indications.
SRE 2023 recommends six key interventions: lifestyle optimization, antibiotics for chronic endometritis, hysteroscopic correction of anatomical issues, salpingectomy for hydrosalpinx, blastocyst stage transfer (if not already done), and PGTA for selected patients. It explicitly discourages routine use of ERA testing, aspirin/LMWH without confirmed thrombophilia, steroids, IVIG, intralipids, or endometrial scratching due to lack of proven benefit.
Male factor contributions, often overlooked, are crucial; optimizing sperm quality through re-evaluation of semen analysis, DNA fragmentation index, and lifestyle modifications is vital. Transfer technique, including soft catheters, ultrasound guidance, and avoiding fundal contact, along with adequate luteal phase support, are also critical. Cycle strategies like single euploid blastocyst frozen embryo transfers are preferred.
Crucially, managing RIF involves acknowledging the significant psychological burden on couples. A patient-centered approach, shared decision-making, realistic prognosis discussions, and sensitivity to other family-building options (e.g., donor gametes, adoption, surrogacy) are paramount. Clinicians must know when to pause, offer a break, and prioritize caring for the couple over achieving a "target" pregnancy at all costs.